Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
TWST

Twist Bioscience Corp

TWST

26.99USD+0.58 (+2.20%)Market Closed
Watchlist

Market Summary

USD26.99+0.58
Market Closed
2.20%

TWST Alerts

  • Losses in recent quarter

TWST Stock Price

View Fullscreen

TWST RSI Chart

TWST Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-7.59

Price/Sales (Trailing)

6.34

EV/EBITDA

-7.26

Price/Free Cashflow

-9.12

TWST Price/Sales (Trailing)

TWST Profitability

Operating Margin

36.61%

EBT Margin

-83.01%

Return on Equity

-32.82%

Return on Assets

-26.35%

Free Cashflow Yield

-10.96%

TWST Fundamentals

TWST Revenue

Revenue (TTM)

245.1M

Revenue Y/Y

16.82%

Revenue Q/Q

5.03%

TWST Earnings

Earnings (TTM)

-204.6M

Earnings Y/Y

9.53%

Earnings Q/Q

19.43%

Price Action

Last 7 days

8.9%

Last 30 days

55.1%

Last 90 days

20.4%

Trailing 12 Months

2.5%

How does TWST drawdown profile look like?

TWST Financial Health

Current Ratio

5.79

TWST Investor Care

Shares Dilution (1Y)

1.83%

Diluted EPS (TTM)

-3.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023227.8M235.5M245.1M0
2022163.1M184.2M203.6M215.8M
2021113.0M126.8M132.3M146.2M
202065.8M73.4M90.1M101.1M
201940.0M47.1M54.4M60.1M
201818.1M21.8M25.4M32.6M
20170010.8M14.4M

Latest Insider Trading transactions for TWST

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 05, 2023
werner robert f.
sold (taxes)
-3,725
24.67
-151
chief accounting officer
Dec 05, 2023
green paula
sold (taxes)
-22,943
24.67
-930
svp of human resources
Dec 05, 2023
cho dennis
sold (taxes)
-6,414
24.67
-260
see remarks
Dec 05, 2023
banyai william
sold (taxes)
-19,119
24.67
-775
see remarks
Dec 05, 2023
leproust emily m.
sold (taxes)
-57,456
24.67
-2,329
chief executive officer
Nov 20, 2023
banyai william
sold (taxes)
-23,948
24.74
-968
see remarks
Nov 20, 2023
leproust emily m.
sold (taxes)
-65,857
24.74
-2,662
chief executive officer
Nov 20, 2023
thorburn james m
sold (taxes)
-25,432
24.74
-1,028
chief financial officer
Nov 20, 2023
green paula
sold (taxes)
-9,228
24.74
-373
svp of human resources
Nov 20, 2023
finn patrick john
sold (taxes)
-25,432
24.74
-1,028
president and coo

1–10 of 50

Which funds bought or sold TWST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
added
94.12
2,568,040
5,352,770
-%
Nov 24, 2023
DEUTSCHE BANK AG\
added
4.85
38,208
1,037,480
-%
Nov 22, 2023
Graham Capital Management, L.P.
new
-
304,203
304,203
0.01%
Nov 21, 2023
COMERICA BANK
new
-
46,395
46,395
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
reduced
-90.00
-96.00
31.00
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
11.5
102,365
1,085,750
-%
Nov 15, 2023
Tudor Investment Corp Et Al
sold off
-100
-575,990
-
-%
Nov 15, 2023
JANE STREET GROUP, LLC
reduced
-38.45
-1,035,910
1,616,890
-%
Nov 15, 2023
Capital Impact Advisors, LLC
added
8.95
68,242
933,925
1.56%
Nov 15, 2023
MORGAN STANLEY
added
22.69
4,006,520
22,645,400
-%

1–10 of 42

Latest Funds Activity

Are funds buying TWST calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TWST
No. of Funds

Schedule 13G FIlings of Twist Bioscience Corp

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 08, 2023
integrated core strategies (us) llc
5.3%
3,042,960
SC 13G
Apr 10, 2023
vanguard group inc
10.02%
5,697,547
SC 13G/A
Apr 06, 2023
blackrock inc.
10.9%
6,212,913
SC 13G/A
Feb 13, 2023
capital world investors
1.2%
704,000
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.24%
5,229,345
SC 13G/A
Feb 03, 2023
state street corp
7.82%
4,426,249
SC 13G
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.18%
2,934,033
SC 13G
Jan 24, 2023
blackrock inc.
9.7%
5,487,180
SC 13G/A
Jan 13, 2023
jpmorgan chase & co
6.7%
3,829,962
SC 13G

Recent SEC filings of Twist Bioscience Corp

View All Filings
Date Filed Form Type Document
Dec 07, 2023
4
Insider Trading
Dec 07, 2023
4
Insider Trading
Dec 07, 2023
4
Insider Trading
Dec 07, 2023
4
Insider Trading
Dec 07, 2023
4
Insider Trading
Nov 22, 2023
4
Insider Trading
Nov 22, 2023
4
Insider Trading
Nov 22, 2023
4
Insider Trading
Nov 22, 2023
4
Insider Trading
Nov 22, 2023
4
Insider Trading

Peers (Alternatives to Twist Bioscience Corp)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
160.7B
29.6B
10.51% -19.98%
27.16
5.44
-5.39% -12.54%
44.1B
3.6B
24.23% 23.99%
53.65
12.3
7.43% 22.86%
37.3B
7.0B
16.28% -18.61%
32.89
5.33
5.03% -14.68%
15.2B
9.3B
1.84% -9.68%
19.95
1.64
-9.69% -38.22%
11.7B
2.4B
2.99% 40.82%
-41.48
4.86
19.99% 60.62%
MID-CAP
10.5B
4.2B
16.20% -2.67%
22.08
2.49
11.49% 8.84%
8.7B
1.8B
2.84% 34.94%
31.81
4.88
29.62% 20.49%
6.9B
988.7M
40.66% 50.03%
-13.86
7
27.41% 8.51%
3.9B
919.1M
17.21% 17.06%
-147.97
4.28
73.02% -172.93%
3.0B
535.8M
8.75% -45.64%
-7.02
5.66
24.38% 26.34%
SMALL-CAP
531.2M
297.1M
54.98% -22.82%
-5.87
1.79
-6.74% -21.60%
71.5M
21.4M
-81.47% -93.49%
-0.62
3.34
-8.80% -39.66%
31.2M
9.2M
-11.33% -33.68%
-1.76
3.4
16.43% 48.38%
12.0M
13.4M
-4.35% -39.31%
-1.21
0.9
-26.43% -20.54%
120.4K
-
-82.76% -93.43%
0
0.76
-57.78% -93.13%

Twist Bioscience Corp News

Latest updates
InvestorsObserver07 Dec 202304:52 pm2 days ago
GuruFocus.com29 Nov 202307:04 pm10 days ago
Beaumont Enterprise17 Nov 202312:52 pm22 days ago
Yahoo Finance17 Nov 202308:00 am22 days ago
InvestorsObserver17 Nov 202308:00 am22 days ago
InvestorsObserver17 Nov 202308:00 am22 days ago
Morningstar17 Nov 202308:00 am22 days ago
Nasdaq17 Nov 202308:00 am22 days ago
InvestorsObserver14 Nov 202308:00 am25 days ago
GuruFocus.com06 Oct 202307:00 am2 months ago
GuruFocus.com20 Sep 202307:00 am2 months ago
The Business Journals16 Jun 202307:00 am5 months ago
Yahoo Finance05 May 202307:00 am7 months ago
The Business Journals05 May 202307:00 am7 months ago
Nasdaq20 Apr 202307:00 am7 months ago

Financials for Twist Bioscience Corp

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue5.0%66,946,00063,740,00060,180,00054,243,00057,306,50056,113,00048,127,00042,018,00037,950,50035,018,00031,204,00028,161,00032,432,00021,207,00019,297,00017,164,00015,736,50013,600,00013,557,00011,492,0008,407,000
Cost Of Revenue1.4%42,424,00041,845,00041,669,00029,442,00031,586,00030,974,00029,714,00027,056,00022,497,00020,933,00019,028,00018,162,00017,577,50016,472,00013,564,00013,792,00012,385,50011,394,00011,789,00011,857,0009,093,000
Costs and Expenses-6.0%117,057,500124,521,000121,817,00098,873,000114,177,500117,276,000108,929,00097,958,00077,761,50077,136,00069,208,00060,954,00056,399,00049,403,00051,383,00072,994,00047,305,00041,721,00039,820,00034,389,00028,111,000
  S&GA Expenses2.9%47,391,50046,057,00053,965,00042,324,00054,159,50053,693,00053,998,00051,098,00038,242,50034,478,00034,389,00028,792,00027,185,00022,487,00027,190,00026,405,00024,423,00021,320,00019,124,00015,259,00012,953,000
  R&D Expenses-3.2%23,745,50024,528,00027,379,00031,242,00029,606,00036,840,00031,231,00022,630,00019,443,00019,838,00015,791,00014,000,00011,636,50010,444,00010,629,00010,297,00010,496,5009,007,0008,907,0007,273,0006,065,000
EBITDA Margin8.1%-0.71-0.77-0.83-0.91-1.04-1.11-1.15-1.14-1.09-1.01-1.01-1.08-1.47-1.90-2.11------
Interest Expenses0%1,0001,0002,0001,00025,500-29,00026,00083,50070,00095,000118,000143,000181,000215,000248,000287,500318,000340,000348,000386,000
Income Taxes-128.0%-174,000622,000676,00076,000303,000-149,000-149,000-10,405,000370,500-2,377,00061,00046,000262,50021,00061,00037,000112,00054,00084,00043,00076,000
Earnings Before Taxes18.2%-46,465,000-56,773,000-58,480,000-41,748,000-50,823,000-60,666,000-60,817,000-55,968,000-40,901,500-42,414,000-37,858,000-32,854,000-24,055,500-28,186,000-31,707,000-55,601,000-31,069,000-27,862,000-25,849,000-22,596,000-19,726,000
EBT Margin5.9%-0.83-0.88-0.93-0.99-1.12-1.19-1.23-1.21-1.16-1.08-1.09-1.16-1.55-2.00-2.22------
Net Income19.4%-46,243,000-57,395,000-59,156,000-41,824,000-51,115,000-60,517,000-60,668,000-45,563,000-41,242,000-40,037,000-37,919,000-32,900,000-24,318,000-28,207,000-31,768,000-55,638,000-31,181,000-27,916,000-25,933,000-22,639,000-19,802,000
Net Income Margin6.2%-0.83-0.89-0.93-0.99-1.07-1.13-1.15-1.13-1.15-1.07-1.09-1.16-1.55-2.00-2.23------
Free Cashflow17.3%-23,097,000-27,921,000-53,341,000-65,894,000-17,729,000-74,767,000-74,310,000-59,436,000-42,892,000-34,902,000-32,950,000-28,561,000-27,427,000-26,316,000-61,408,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-4.2%7768108549109619801,022786702725677700399408324192187207140164116
  Current Assets-4.8%42444648954259662466438554657760863433534526012916018312114796.00
    Cash Equivalents-5.9%28930731531737937840919346747740135094.0020918527.0047.0069.0029.0067.0082.00
  Inventory-11.8%32.0036.0040.0045.0039.0043.0045.0040.0032.0021.0016.0013.0012.0013.0011.007.007.005.004.006.006.00
  Net PPE-6.4%13214114714513912792.0065.0044.0038.0032.0027.0025.0024.0023.0021.0021.0020.0015.0014.0012.00
  Goodwill0%86.0086.0086.0086.0086.0086.0086.0084.0022.0023.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities0.1%15315315016417215915816012111563.0062.0063.0059.0060.0089.0035.0031.0025.0026.0027.00
  Current Liabilities0.7%73.0073.0072.0084.0091.0093.0085.0080.0063.0055.0040.0037.0036.0031.0030.0058.0030.0025.0019.0019.0019.00
    LT Debt, Current---------2.002.003.003.003.003.003.003.003.003.003.003.003.00
    LT Debt, Non Current------------1.001.002.003.004.004.005.006.007.007.00
Shareholder's Equity-5.2%623658704746789821863626581610614638336349264103152176115139-
  Retained Earnings-4.7%-1,033-986-929-870-828-777-716-656-610-569-529-491-458-434-405-374-318-287-259-233-210
  Additional Paid-In Capital0.7%1,6571,6451,6331,6171,6201,5991,5811,2821,1911,1791,1431,1297957836704774704633753729.00
Shares Outstanding0.3%58.0057.0057.0057.0057.0053.0053.0050.0049.0049.0047.0046.0039.0037.0037.0033.0027.0030.0024.00--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations11.6%-20,704,000-23,412,000-44,288,000-54,070,000-1,267,000-34,125,000-42,340,000-46,653,000-34,803,000-27,960,000-24,549,000-24,932,000-25,202,000-23,468,000-58,671,000-34,914,000-23,358,000-22,082,000-20,813,000-21,684,000-16,696,000
  Share Based Compensation10.9%11,747,00010,597,00010,259,000-2,325,00019,048,00020,043,00022,465,00018,108,0009,247,0009,176,00011,553,0007,022,0005,131,0004,071,0004,197,0003,697,0003,363,0003,032,0002,911,0001,864,0001,086,000
Cashflow From Investing-112.0%-2,247,00018,670,00041,160,000-6,971,0002,783,0004,163,000-13,294,000-226,582,00023,911,000104,575,00073,590,000-45,921,000-94,669,000-61,149,00028,763,00012,405,000-1,187,000-22,706,000-15,160,000-65,757,000404,000
Cashflow From Financing166.9%442,000-661,0001,525,000-395,0001,240,000-1,311,000271,616,000-1,011,0001,575,000-765,0001,451,000326,921,0005,574,000108,064,000188,037,0002,057,0002,928,00084,285,000-1,634,00072,999,0006,583,000
  Buy Backs----------------------

TWST Income Statement

2023-09-30
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]   
Revenues [1][1]$ 245,109$ 203,565$ 132,333
Operating expenses:   
Cost of revenues155,380119,33080,620
Research and development106,894120,30769,072
Selling, general and administrative189,738212,949135,901
Restructuring and other costs16,16900
Change in fair value of contingent considerations and holdbacks(5,913)(14,245)(534)
Total operating expenses462,268438,341285,059
Loss from operations(217,159)(234,776)(152,726)
Interest income14,3653,062435
Interest expense(5)(80)(367)
Gain on deconsolidation of subsidiary04,6070
Other income (expense), net(667)(1,087)(1,370)
Loss before income taxes(203,466)(228,274)(154,028)
(Provision for) benefit from income taxes(1,152)10,4111,930
Net loss attributable to common stockholders(204,618)(217,863)(152,098)
Other comprehensive loss:   
Change in unrealized gain (loss) on investments1,510(1,594)(14)
Foreign currency translation adjustment(423)(795)473
Comprehensive loss$ (203,531)$ (220,252)$ (151,639)
Net loss per share attributable to common stockholders—basic (in dollars per share)$ (3.60)$ (4.04)$ (3.15)
Net loss per share attributable to common stockholders—diluted (in dollars per share)$ (3.60)$ (4.04)$ (3.15)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares)56,88553,88548,251
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares)56,88553,88548,251
[1]During the years ended September 30, 2023, and 2022, the Company had revenues from the related parties in the amount of $5.9 million and $3.5 million, respectively. The revenues from the related parties were immaterial for the year ended September 30, 2021.

TWST Balance Sheet

2023-09-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Sep. 30, 2022
Current assets:  
Cash and cash equivalents$ 286,470$ 378,687
Short-term investments49,943126,281
Accounts receivable, net44,06440,294
Inventories32,06339,307
Prepaid expenses and other current assets11,71611,914
Total current assets424,256596,483
Property and equipment, net131,830139,441
Operating lease right-of-use assets71,53174,948
Goodwill85,81185,811
Intangible assets, net54,48359,738
Restricted cash, non-current2,8111,572
Other non-current assets5,6813,385
Total assets776,403961,378
Current liabilities:  
Accounts payable14,05220,092
Accrued expenses10,75410,169
Accrued compensation25,81827,023
Current portion of operating lease liability14,89613,642
Other current liabilities7,80319,737
Total current liabilities73,32390,663
Operating lease liability, net of current portion79,17381,270
Other non-current liabilities47560
Total liabilities152,971171,993
Commitments and contingencies
Stockholders’ equity  
Common stock, $0.00001 par value — 100,000 and 100,000 shares authorized at September 30, 2023 and 2022, respectively; 57,557 and 56,523 shares issued and outstanding at September 30, 2023 and 2022, respectively00
Additional paid-in capital1,657,2221,619,644
Accumulated other comprehensive loss(756)(1,843)
Accumulated deficit(1,033,034)(828,416)
Total stockholders’ equity623,432789,385
Total liabilities and stockholders’ equity$ 776,403$ 961,378
TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEwww.twistbioscience.com
 EMPLOYEES989

Twist Bioscience Corp Frequently Asked Questions


What is the ticker symbol for Twist Bioscience Corp? What does TWST stand for in stocks?

TWST is the stock ticker symbol of Twist Bioscience Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Twist Bioscience Corp (TWST)?

As of Fri Dec 08 2023, market cap of Twist Bioscience Corp is 1.55 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TWST stock?

You can check TWST's fair value in chart. The fair value of Twist Bioscience Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Twist Bioscience Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TWST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Twist Bioscience Corp a good stock to buy?

The fair value guage provides a quick view whether TWST is over valued or under valued. Whether Twist Bioscience Corp is cheap or expensive depends on the assumptions which impact Twist Bioscience Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TWST.

What is Twist Bioscience Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, TWST's PE ratio (Price to Earnings) is -7.59 and Price to Sales (PS) ratio is 6.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TWST PE ratio will change depending on the future growth rate expectations of investors.